Clinical trial

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-11-01

PhasePHASE4

Study timeline

Study start (unknown)2007-11-01Date precision: month

Registry last updated2018-11-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Schizoaffective Disorderunresolved

Diabetesunresolved

Weight Gainunresolved

Interventions

PramlintideDRUG · verified · RxNorm: pramlintide

PlaceboDRUG

Sponsors & collaborators

University of Texas Southwestern Medical Centerlead sponsor

Amylin Pharmaceuticals, LLC.collaborator

Mapped research locations

DallasTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00690235 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.